Core Points - PharmaCorp Rx Inc. has received approval from the TSX Venture Exchange for the supplemental listing of 27,427,500 common share purchase warrants, expected to trade under the symbol PCRX.WT starting November 17, 2025 [1][2] - The Offering closed on November 12, 2025, with a total of 54,855,000 Units issued, each consisting of one common share and one-half of a common share purchase warrant, with an exercise price of $0.50 per Warrant Share [2] Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [4] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire both bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform [4]

Core Points - PharmaCorp Rx Inc. has successfully closed a bought deal public offering, raising approximately C$23.0 million through the sale of 54,855,000 units at C$0.42 per unit, including the full exercise of the over-allotment option [1][2] - Each unit consists of one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of additional shares at C$0.50 until November 12, 2027 [2] - The net proceeds from the offering will be allocated for future acquisition opportunities and general working capital [3] Offering Details - Directors and officers of the company participated in the offering, acquiring a total of 3,762,010 units, which is classified as a related party transaction [4] - The underwriters received a cash commission of 6.0% of the gross proceeds, totaling C$1,134,633, and were issued 2,026,130 broker warrants [5] - The offering was conducted under a prospectus supplement dated November 7, 2025, linked to the company's base shelf prospectus filed with Canadian securities authorities [6] Company Overview - PharmaCorp is a Canadian pharmacy acquisition platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [7] - The company operates seven pharmacies under the PharmaChoice Canada banner and aims to expand its network by acquiring both bannered and independent pharmacies [7] - PharmaCorp actively seeks discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [8][9]

Financial Data and Key Metrics Changes - Revenue grew 20% to $377.4 million, with adjusted EBITDA rising 19% to $27.3 million, yielding adjusted EPS of $0.25 [5][14][15] - Total resident count increased by 13% to 203,766, driven by both organic growth and acquisitions [5][14] - Adjusted EBITDA margins held steady at 7.2%, reflecting the dilutive impact from recent acquisitions and greenfield startups [5][15] Business Line Data and Key Metrics Changes - The pharmacy segment experienced strong performance, with significant contributions from new acquisitions in Washington and Oregon [14][15] - Gross profit increased to $74.7 million, with a margin of 19.8% [15] - The company noted that its four- to five-year locations are performing at or above the consolidated adjusted EBITDA margin, while newer locations are progressing steadily [15] Market Data and Key Metrics Changes - Guardian holds a national market share of 13% in serving assisted living facilities, with 37 pharmacies having over 20% market share and 12 pharmacies exceeding 40% [8][9] - The company serves nearly 204,000 residents, primarily in-house, and expects to benefit from demographic trends as the aging population grows [9][10] Company Strategy and Development Direction - The company aims to drive organic growth through new customer facility wins, higher resident adoption, and greenfield expansions, while also pursuing targeted acquisitions [10][11] - Guardian is focused on enhancing profitability by integrating new pharmacies and leveraging technology and operational efficiencies [10][11] - The company is navigating policy changes proactively and advocating for legislative solutions to address industry challenges [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in offsetting anticipated EBITDA headwinds despite expected flat revenue growth in 2026 [6][10] - The company highlighted the importance of local leadership and scale in executing its growth strategy [7][10] - Management noted that the acquisition pipeline remains active, with a disciplined approach to selecting operators and markets [18] Other Important Information - The company filed an S-3 shelf registration for up to 6 million shares to provide financial flexibility [12] - Cash position improved to $36 million, with strong cash generation and no debt outstanding [17] Q&A Session Summary Question: Comparison of vaccine program contribution this year to last year - Management noted steady performance in the vaccine program, with a stronger start in September compared to last year [22][23] Question: Resident count and acquisition impact - Management confirmed that recent acquisitions are included in the Q3 resident count, with expectations for steady growth in Q4 [24][25] Question: Status of negotiations with PBMs regarding IRA issues - Management indicated that discussions are ongoing and they are growing more confident in offsetting headwinds [26][27] Question: Margin impact from acquisitions - Management highlighted that recent acquisitions are dilutive to margins but are expected to improve over time as they mature [33][41] Question: Changes in Medicare Part D plans and resident switching - Management stated it is early in the process to assess the impact of changes in Part D plans, with ongoing efforts to optimize plans for residents [46][48] Question: Changes in drug consumption patterns - Management observed a steady growth in acuity among residents, leading to increased utilization of certain brand medications [50]

Core Insights - The Chinese retail pharmacy sector, with approximately 700,000 stores and an average of 4.3 pharmacies per 10,000 people, is positioned as a crucial health service point for the public, yet it remains primarily focused on selling medications rather than providing comprehensive health services [1][2] - The establishment of the Social Pharmacy Committee aims to facilitate the transformation of retail pharmacies into health service providers, integrating traditional Chinese medicine (TCM) with modern healthcare practices to enhance community health management [3][4] Group 1: Current Challenges - The retail pharmacy industry in China is undergoing significant changes, with many pharmacies resorting to low-price sales, leading to some exiting the insurance system, indicating a shift towards high-quality development [2] - Experts emphasize that social pharmacies must transition from being merely drug suppliers to becoming integral parts of the national health governance system, taking on greater responsibilities in community health management [2][5] Group 2: Strategic Initiatives - The Social Pharmacy Committee is focused on creating a comprehensive health service system that integrates prevention, care, treatment, and rehabilitation, leveraging the extensive network of pharmacies and the expertise of over 140,000 licensed pharmacists [3][4] - Initiatives include developing standards for integrated services that combine TCM with pharmacy practices, promoting the use of classic TCM prescriptions, and enhancing the role of pharmacists in chronic disease management and public health promotion [3][4] Group 3: Future Directions - The committee aims to establish a community health management data platform to address the fragmentation of health services and improve the integration of care between hospitals and pharmacies [4] - There is a call for collaboration between medical institutions and pharmacies to create standardized health management practices, ensuring a seamless transition from treatment to prevention and health promotion [5]

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 47.7 million units at C$0.42 per unit, aiming to raise C$20.0 million due to strong investor demand [1][3] Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2] - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3] - An over-allotment option allows underwriters to purchase an additional 15% of the units sold to cover over-allotments [4] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for future acquisition opportunities and general working capital [3] Group 3: Company Overview - PharmaCorp is focused on acquiring and operating community pharmacies in Canada, empowering pharmacists as equity partners [7] - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies [8]

Core Viewpoint - PharmaCorp Rx Inc. has announced a bought deal offering of 35.7 million units at a price of C$0.42 per unit, aiming to raise gross proceeds of C$15.0 million for future acquisitions and working capital [1][3]. Group 1: Offering Details - The offering consists of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at C$0.50 for 24 months [2]. - The closing of the offering is expected around November 12, 2025, pending regulatory approvals [3]. - The underwriters have an over-allotment option to purchase an additional 15% of the units sold to cover over-allotments and for market stabilization [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards future acquisition opportunities and general working capital requirements [3]. Group 3: Company Overview - PharmaCorp is a Canadian pharmacy acquisition platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [7]. - The company operates seven pharmacies under the PharmaChoice Canada banner and plans to continue acquiring both bannered and independent pharmacies across Canada [8].

Core Viewpoint - PharmaCorp RX Inc. has filed its Final Short Form Base Shelf Prospectus, allowing the company to raise up to $100 million through various securities over a 25-month period, enhancing its capacity for strategic acquisitions and growth [2][3]. Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [5]. - The company operates seven pharmacies under the PharmaChoice Canada banner and aims to expand its network by acquiring both bannered and independent pharmacies across Canada [5]. Financial Strategy - The Prospectus enables PharmaCorp to qualify the distribution of common shares, preferred shares, warrants, debt securities, subscription receipts, units, or any combination thereof [2]. - The specific terms of any future offerings will be determined in a Prospectus supplement, which will be filed with Canadian securities regulatory authorities [2]. Growth and Expansion Plans - The filing of the Prospectus is seen as a significant step in PharmaCorp's growth journey, providing the flexibility to access capital efficiently for strategic acquisitions and expansion opportunities [3]. - The company is positioned to accelerate its national growth strategy and strengthen its operational platform through its alliance with PharmaChoice Canada [3].

Core Insights - CVS Pharmacy has completed the acquisition of select Rite Aid and Bartell Drugs assets, enhancing its pharmacy services in the Pacific Northwest and serving millions of customers [1][2]. Expansion across the Pacific Northwest - CVS now operates 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon, and Washington [2]. - The company has acquired prescription files from 626 former Rite Aid and Bartell Drugs pharmacies across 15 states, allowing CVS to serve over nine million patients [2]. Recruitment and Investment to Support Pharmacy Operations - CVS has hired more than 3,500 former employees from Rite Aid and Bartell Drugs to maintain service standards and ensure timely prescription support [4]. - Targeted investments have been made in existing pharmacy locations to improve staff scheduling, recruitment, and training [4]. Transaction Finalised Following Bankruptcy Court Approval - The acquisition was approved by the US Bankruptcy Court for the District of New Jersey in May 2025, and the entire transaction was completed in under four months [6]. - The final store acquisitions were concluded on September 30, with locations in Bend, Oregon, and Bainbridge Island, Washington [6]. Key Factors in Acquisition Decisions - CVS prioritized convenience and access to essential prescriptions when selecting Rite Aid locations and prescription files for acquisition [7]. - Most CVS stores receiving transferred prescription files are within three miles of existing Rite Aid branches, with nearly half within one mile, minimizing disruption for affected patients and communities [7].

Core Insights - CVS has acquired customer prescription files from hundreds of closed Rite Aid stores and is now operating 63 former Rite Aid locations in Idaho, Oregon, and Washington [1] - Rite Aid has filed for bankruptcy protection and is in the process of selling most of its assets, having previously operated over 4,000 stores [2] - After emerging from Chapter 11 reorganization in 2024, Rite Aid's store count has decreased to around 1,200, indicating ongoing struggles in a challenging retail environment [3] Company Developments - CVS Health has not disclosed the financial details of its acquisition of Rite Aid's stores and prescription files [1] - The company operates several thousand drugstores and has a significant pharmacy benefits management business, along with an Aetna health insurance segment covering nearly 27 million people [5] Industry Trends - The pharmacy sector is facing challenges such as increased theft and a shift of customers towards online shopping and discount retailers [4] - Major chains like Walgreens are also undergoing changes, with Walgreens agreeing to be acquired by private equity firm Sycamore Partners [4]

Core Points - Kroger Health, in collaboration with the Cardinal Health Foundation, is participating in the National Prescription Drug Take Back Day on October 25, allowing individuals to safely dispose of unused or expired medications at local pharmacies [1][2][3] - The initiative aims to promote safer environments and educate communities on medication safety, contributing to healthier living [3][4] Company Overview - Kroger Health serves over 17 million patients annually and operates more than 2,200 pharmacies across 35 states, along with telehealth services and in-person clinics [5] - The Cardinal Health Foundation focuses on advancing health equity and supports initiatives that foster healthier communities [6] Event Details - Drug take back events will occur from 10 a.m. to 2 p.m. local time, with law enforcement present to accept various forms of medications [3][4] - Since 2018, Kroger Health has collected over 220,000 pounds of unwanted medications and served more than 86,000 visitors during these events [4]